208 related articles for article (PubMed ID: 16896006)
1. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
Gordon MS; Matei D; Aghajanian C; Matulonis UA; Brewer M; Fleming GF; Hainsworth JD; Garcia AA; Pegram MD; Schilder RJ; Cohn DE; Roman L; Derynck MK; Ng K; Lyons B; Allison DE; Eberhard DA; Pham TQ; Dere RC; Karlan BY
J Clin Oncol; 2006 Sep; 24(26):4324-32. PubMed ID: 16896006
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
Agus DB; Sweeney CJ; Morris MJ; Mendelson DS; McNeel DG; Ahmann FR; Wang J; Derynck MK; Ng K; Lyons B; Allison DE; Kattan MW; Scher HI
J Clin Oncol; 2007 Feb; 25(6):675-81. PubMed ID: 17308272
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Herbst RS; Davies AM; Natale RB; Dang TP; Schiller JH; Garland LL; Miller VA; Mendelson D; Van den Abbeele AD; Melenevsky Y; de Vries DJ; Eberhard DA; Lyons B; Lutzker SG; Johnson BE
Clin Cancer Res; 2007 Oct; 13(20):6175-81. PubMed ID: 17947484
[TBL] [Abstract][Full Text] [Related]
5. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer.
Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4436s-4440s. PubMed ID: 16857824
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab for the treatment of ovarian cancer.
Langdon SP; Faratian D; Nagumo Y; Mullen P; Harrison DJ
Expert Opin Biol Ther; 2010 Jul; 10(7):1113-20. PubMed ID: 20465533
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.
Yamamoto N; Yamada Y; Fujiwara Y; Yamada K; Fujisaka Y; Shimizu T; Tamura T
Jpn J Clin Oncol; 2009 Apr; 39(4):260-6. PubMed ID: 19261664
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
Agus DB; Gordon MS; Taylor C; Natale RB; Karlan B; Mendelson DS; Press MF; Allison DE; Sliwkowski MX; Lieberman G; Kelsey SM; Fyfe G
J Clin Oncol; 2005 Apr; 23(11):2534-43. PubMed ID: 15699478
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
Pegram MD; Lipton A; Hayes DF; Weber BL; Baselga JM; Tripathy D; Baly D; Baughman SA; Twaddell T; Glaspy JA; Slamon DJ
J Clin Oncol; 1998 Aug; 16(8):2659-71. PubMed ID: 9704716
[TBL] [Abstract][Full Text] [Related]
11. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
Gianni L; Lladó A; Bianchi G; Cortes J; Kellokumpu-Lehtinen PL; Cameron DA; Miles D; Salvagni S; Wardley A; Goeminne JC; Hersberger V; Baselga J
J Clin Oncol; 2010 Mar; 28(7):1131-7. PubMed ID: 20124183
[TBL] [Abstract][Full Text] [Related]
12. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.
Kristjansdottir K; Dizon D
Expert Opin Biol Ther; 2010 Feb; 10(2):243-50. PubMed ID: 20001562
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors.
Albanell J; Montagut C; Jones ET; Pronk L; Mellado B; Beech J; Gascon P; Zugmaier G; Brewster M; Saunders MP; Valle JW
Clin Cancer Res; 2008 May; 14(9):2726-31. PubMed ID: 18451238
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
17. HER3 mRNA as a predictive biomarker in anticancer therapy.
Amler LC
Expert Opin Biol Ther; 2010 Sep; 10(9):1343-55. PubMed ID: 20695834
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
J Clin Oncol; 1996 Mar; 14(3):737-44. PubMed ID: 8622019
[TBL] [Abstract][Full Text] [Related]
19. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]